Does Medical Cannabis Reduce Opioid Use in Adults With Pain
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Pain
- Marijuana
- Opioid Use
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 99 years
- Gender
- Both males and females
Description
This study will examine how medical cannabis use affects opioid analgesic use, with particular attention to THC/CBD content and adverse events. We will enroll adults with (a) severe or chronic neuropathic or joint pain, (b) prescribed opioid analgesic use, (c) active certification for medical cannab...
This study will examine how medical cannabis use affects opioid analgesic use, with particular attention to THC/CBD content and adverse events. We will enroll adults with (a) severe or chronic neuropathic or joint pain, (b) prescribed opioid analgesic use, (c) active certification for medical cannabis, and (d) intends to have soft gel capsule products dispensed at Vireo (medical cannabis dispensary) (including a high THC:low CBD product, an equal THC:CBD product, and a low THC:high CBD product). Over the 14 weeks, data sources will include questionnaires; medical, pharmacy, and Prescription Monitoring Program (PMP) records; and urine samples. The primary independent variable will be type of soft gel capsule product, and the primary outcome will be cumulative opioid analgesic dose.
Tracking Information
- NCT #
- NCT04308148
- Collaborators
- Laura and John Arnold Foundation
- Vireo Health
- Investigators
- Principal Investigator: Julia Arnsten, MD, MPH Albert Einstein College of Medicine
Get Well Soon